J Korean Diabetes Assoc.  2006 Mar;30(2):104-111. 10.4093/jkda.2006.30.2.104.

Serum Adiponectin, TNF-alpha, IL-6 and Insulin Resistance in Women with Polycystic Ovary Syndrome

• Kim YA
• Noh JH
• Kim DJ
• Um TH
• Cho CR
• Jang NY
• Kwon SK
• Lee SH
• Park JH
• Ko KS
• Rhee BD
• Lim KH

• KMID: 2063439
• DOI: http://doi.org/10.4093/jkda.2006.30.2.104

Abstract

BACKGROUND
To determine plasma adipokines such as adiponectin, IL-6 and TNF-alpha concentrations in women with and without polycystic ovary syndrome (PCOS) and to assess possible correlations of adipocytokines to the hormonal and metabolic parameters, including measures of insulin resistance (IR).
METHODS
Forty-four selected women were classified as follows: 13 obese (body mass index [BMI] > or = 25 kg/m(2)) with PCOS; 15 non-obese (BMI < 25 kg/m(2)) with PCOS; 8 obese without PCOS, and 8 non-obese without PCOS. Blood samples were collected from all women with or without PCOS after an overnight fast. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, 17-alpha-hydroxyprogesterone, dehydroepiandrosterone sulfate (DHEA-S), sex hormone-binding globulin (SHBG), insulin, glucose, adiponectin, TNF-alpha and IL-6 were measured. Measures of IR included HOMA-IR and QUICKI.
RESULTS
In non-obese group, fasting insulin levels and HOMA-IR in PCOS were significantly higher compared to control. However, Adiponectin, TNF-alpha and IL-6 concentrations were found not to be different in obese women with PCOS as compared with obese women without PCOS and in non-obese women with PCOS as compared with non-obese women without PCOS. Adiponectin concentrations correlated inversely with BMI, waist circumference (WC), total fat mass, serum insulin, and HOMA-IR in PCOS group. However, multiple regression analysis showed that BMI was the only independent determinant of adiponectin concentration.
CONCLUSION
Our results suggest that insulin sensitivity per se probably does not play any role in the control of adipokines levels such as adiponectin, TNF-alpha and IL-6 in PCOS women

Keyword

Adiponectin; IL-6; PCOS; TNF-alpha

MeSH Terms

17-alpha-Hydroxyprogesterone
Adipokines
Adiponectin*
Dehydroepiandrosterone Sulfate
Fasting
Female
Follicle Stimulating Hormone
Glucose
Humans
Insulin Resistance*
Insulin*
Interleukin-6*
Luteinizing Hormone
Plasma
Polycystic Ovary Syndrome*
Sex Hormone-Binding Globulin
Testosterone
Tumor Necrosis Factor-alpha*
Waist Circumference
17-alpha-Hydroxyprogesterone
Adipokines
Adiponectin
Dehydroepiandrosterone Sulfate
Follicle Stimulating Hormone
Glucose
Insulin
Interleukin-6
Luteinizing Hormone
Sex Hormone-Binding Globulin
Testosterone
Tumor Necrosis Factor-alpha

Figure

• 

  Fig. 1 Serum adipokines levels of PCOS and controls according to BMI. *P < 0.05

Reference

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999. 84:1897–1899.

2. Legro RS. Polycystic ovary syndrome: the new millennium. Mol Cell Endocrinol. 2001. 184:87–93.

3. Dunaif A. Bjorntorp P, Brodoff BN, editors. Polycystic ovary syndrome and obesity. Obesity. 1992. Philadelphia: Lippincott;594–606.

4. Burghen GA, Givens JR, Kitabachi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab. 1990. 50:113–116.

5. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999. 84:165–169.

6. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod. 2001. 16:1995–1998.

7. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000. 73:150–156.

8. Sam S, Danif A. Polycystic ovary syndrome: Syndrome XX? Trends Endocrinol Metab. 2003. 14:365–370.

9. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003. 26:2442–2450.

10. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004. 89:2548–2556.

11. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.

12. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectimia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.

13. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003. 16:72–75.

14. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002. 87:2764–2769.

15. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentration of a novel adipose specific protein adiponectin in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000. 20:1595–1599.

16. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001. 50:1126–1133.

17. Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003. 52:239–242.

18. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001. 7:941–946.

19. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001. 86:2453–2455.

20. Gonzalez F, Thusu K, Abdel-Rahman E, Prahala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor in normal-weight women with polycystic ovary syndrome. Metabolism. 1999. 48:437–441.

21. Orio F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, Zullo F, Colao A, Lombardi G, Vettor R. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003. 88:2619–2623.

22. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Human reprod. 2003. 18:1790–1796.

24. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab. 2004. 89:1592–1597.

25. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia. 2003. 46:625–633.

26. Ardawi MS, Rouzi A. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2004. 83:1708–1716.

27. Plymate SR, Matej LA, Jones RO, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 1988. 67:460–464.

28. Crave JC, Lejeune H, Brebant C, Baret C, Pugeat M. Differential effects of insulin and insulin-like growth factor I on the production on plasma steroid binding globulins by human hepatoblastoma-derived (HepG2) cells. J Clin Endocrinol Metab. 1995. 80:1283–1289.

29. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T. Concentrations of sex-hormone binding globulin corticosteroidbinding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem. 1986. 32:146–152.

30. Mingrone G, Greco AV, Giancaterini A, Scarfone A, Castagneto M, Pugeat M. Sex hormone-binding globulin levels and cardiovascular risk factors in morbidly obese subjects before and after weight reduction induced by diet or malabsorptive surgery. Atherosclerosis. 2002. 161:455–462.